<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>2(6)</volume><submitter>Gilbertson DT</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>In patients on dialysis with anemia, avoiding red blood cell transfusions is preferable. We sought to develop and validate a novel transfusion prediction risk score for patients receiving maintenance hemodialysis.&lt;h4>Methods&lt;/h4>This retrospective cohort study used United States Renal Data System data to create a model development cohort (patients who were point prevalent and on hemodialysis on November 1, 2012) and a validation cohort (patients who were point prevalent and on hemodialysis on August 1, 2013). We characterized comorbidity, inflammatory conditions, hospitalizations, anemia and anemia management, iron parameters, intravenous iron use, and vitamin D use during a 6-month baseline period to predict subsequent 3-month transfusion risk. We used logistic least ab</pubmed_abstract><journal>Kidney360</journal><pagination>948-954</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8791373</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Development and Validation of a Transfusion Risk Score for Patients Receiving Maintenance Hemodialysis.</pubmed_title><pmcid>PMC8791373</pmcid><pubmed_authors>Peng Y</pubmed_authors><pubmed_authors>Liu J</pubmed_authors><pubmed_authors>Li S</pubmed_authors><pubmed_authors>Sinsakul M</pubmed_authors><pubmed_authors>Xu H</pubmed_authors><pubmed_authors>Gilbertson DT</pubmed_authors><pubmed_authors>Yan H</pubmed_authors><pubmed_authors>Wetmore JB</pubmed_authors></additional><is_claimable>false</is_claimable><name>Development and Validation of a Transfusion Risk Score for Patients Receiving Maintenance Hemodialysis.</name><description>&lt;h4>Background&lt;/h4>In patients on dialysis with anemia, avoiding red blood cell transfusions is preferable. We sought to develop and validate a novel transfusion prediction risk score for patients receiving maintenance hemodialysis.&lt;h4>Methods&lt;/h4>This retrospective cohort study used United States Renal Data System data to create a model development cohort (patients who were point prevalent and on hemodialysis on November 1, 2012) and a validation cohort (patients who were point prevalent and on hemodialysis on August 1, 2013). We characterized comorbidity, inflammatory conditions, hospitalizations, anemia and anemia management, iron parameters, intravenous iron use, and vitamin D use during a 6-month baseline period to predict subsequent 3-month transfusion risk. We used logistic least ab</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Jun</publication><modification>2025-04-04T07:47:55.044Z</modification><creation>2025-04-04T07:47:55.044Z</creation></dates><accession>S-EPMC8791373</accession><cross_references><pubmed>35373092</pubmed><doi>10.34067/kid.0004512020</doi><doi>10.34067/KID.0004512020</doi></cross_references></HashMap>